Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PCRX Stock Forecast 2026-2027
$23.25
Current Price
$1.02B
Market Cap
Buy 4
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to PCRX Price Targets
+63.4%
To High Target of $38.00
+16.1%
To Median Target of $27.00
-5.4%
To Low Target of $22.00
PCRX Price Momentum
+2.4%
1 Week Change
+3.6%
1 Month Change
-1.9%
1 Year Change
-10.2%
Year-to-Date Change
-15.9%
From 52W High of $27.64
+23.7%
From 52W Low of $18.80
📊 TOP ANALYST CALLS
Did PCRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pacira is one of their latest high-conviction picks.
Latest PCRX Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, PCRX has a bullish consensus with a median price target of $27.00 (ranging from $22.00 to $38.00). The overall analyst rating is Buy (7.7/10). Currently trading at $23.25, the median forecast implies a 16.1% upside. This outlook is supported by 4 Buy, 2 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 63.4% upside. Conversely, the most conservative target is provided by Serge Belanger at Needham, suggesting a 5.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PCRX Analyst Ratings
4
Buy
2
Hold
1
Sell
PCRX Price Target Range
Low
$22.00
Average
$27.00
High
$38.00
Current: $23.25
Latest PCRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PCRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2026 | Barclays | Glen Santangelo | Equal-Weight | Maintains | $25.00 |
| Jan 9, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $38.00 |
| Jan 9, 2026 | Needham | Serge Belanger | Buy | Maintains | $30.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Equal-Weight | Initiates | $27.00 |
| Nov 17, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Assumes | $38.00 |
| Nov 7, 2025 | Truist Securities | Les Sulewski | Buy | Maintains | $28.00 |
| May 9, 2025 | Needham | Serge Belanger | Buy | Maintains | $30.00 |
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $32.00 |
| Apr 8, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $65.00 |
| Feb 28, 2025 | Needham | Serge Belanger | Buy | Maintains | $32.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $70.00 |
| Feb 28, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $24.00 |
| Jan 30, 2025 | Truist Securities | Les Sulewski | Hold | Upgrade | $25.00 |
| Jan 14, 2025 | RBC Capital | Gregory Renza | Sector Perform | Reiterates | $18.00 |
| Jan 13, 2025 | Needham | Serge Belanger | Buy | Maintains | $30.00 |
| Dec 17, 2024 | Needham | Serge Belanger | Buy | Maintains | $30.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $39.00 |
| Nov 12, 2024 | Barclays | Balaji Prasad | Equal-Weight | Maintains | $17.00 |
| Nov 8, 2024 | Needham | Serge Belanger | Buy | Reiterates | $22.00 |
| Nov 7, 2024 | RBC Capital | Gregory Renza | Sector Perform | Maintains | $16.00 |
Pacira BioSciences Inc. (PCRX) Competitors
The following stocks are similar to Pacira based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pacira BioSciences Inc. (PCRX) Financial Data
Pacira BioSciences Inc. has a market capitalization of $1.02B with a P/E ratio of 141.3x. The company generates $726.41M in trailing twelve-month revenue with a 1.0% profit margin.
Revenue growth is +5.1% quarter-over-quarter, while maintaining an operating margin of -1.2% and return on equity of +1.0%.
Valuation Metrics
Market Cap
$1.02B
Enterprise Value
$1.08B
P/E Ratio
141.3x
PEG Ratio
-1.6x
Price/Sales
1.3x
Growth & Margins
Revenue Growth (YoY)
+5.1%
Gross Margin
+79.5%
Operating Margin
-1.2%
Net Margin
+1.0%
EPS Growth
-89.8%
Financial Health
Cash/Price Ratio
+25.3%
Current Ratio
4.5x
Debt/Equity
60.3x
ROE
+1.0%
ROA
+1.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pacira BioSciences Inc. (PCRX) Business Model
About Pacira BioSciences Inc.
What They Do
Develops non-opioid pain management therapies.
Business Model
The company generates revenue by developing, manufacturing, and selling innovative non-opioid pain management products, primarily targeting acute and chronic pain. Its flagship product, EXPAREL, is a long-acting local anesthetic, while iovera offers targeted cryoneurolysis. The company focuses on enhancing patient recovery and reducing opioid dependence in various clinical settings.
Additional Information
Pacira BioSciences Inc. is committed to patient safety and ethical standards in its operations. With a pipeline that includes gene therapy candidates like PCRX-201 aimed at treating chronic inflammation, the company is positioned to expand its product offerings and meet growing market demands. The company is headquartered in Tampa, Florida, and serves hospitals, surgery centers, and healthcare professionals.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
825
CEO
Mr. Frank D. Lee
Country
United States
IPO Year
2011
Website
www.pacira.comPacira BioSciences Inc. (PCRX) Latest News & Analysis
Latest News
Quick Summary
Pacira BioSciences announced studies showing that its product EXPAREL® lowers total care costs in total knee arthroplasty and spinal fusion compared to alternatives. Findings will be presented at the ORS 2026 Annual Meeting.
Why It Matters
Pacira BioSciences' findings on EXPAREL's cost-effectiveness in surgeries could enhance market demand, reduce healthcare costs, and potentially boost the company's stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
28 days ago
Quick Summary
Pacira's stock has declined 56% over the past decade and 68% in five years, with missed earnings and lowered guidance. DOMA Perpetual Capital has nominated three candidates for board positions.
Why It Matters
Pacira's significant stock decline signals deep management issues and lack of profitability. DOMA's push for leadership change may lead to strategic shifts, impacting future performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Pacira BioSciences, Inc. (PCRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
29 days ago
Quick Summary
Pacira BioSciences, Inc. (PCRX) presented at the Barclays 28th Annual Global Healthcare Conference, discussing its business and financial outlook.
Why It Matters
Pacira BioSciences' presentation at a major healthcare conference can influence investor sentiment, signaling potential growth opportunities and attracting interest in its products and pipeline.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
DOMA has issued a statement regarding its nomination of director candidates, indicating that no shareholder action is necessary at this time.
Why It Matters
The statement indicates a potential shift in governance or strategy at DOMA, which can affect investor confidence, stock performance, and future decision-making.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pacira BioSciences granted inducement awards to three new employees on March 3, 2026, under its 2014 Inducement Plan, approved by the Board's Committee without stockholder approval.
Why It Matters
The granting of inducement awards suggests Pacira is investing in talent, which could enhance innovation and growth, impacting future performance and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
1 month ago
Quick Summary
Pacira BioSciences, Inc. (Nasdaq: PCRX) will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, at 2:30 PM ET in Miami.
Why It Matters
Pacira's participation in a major healthcare conference highlights its industry presence and commitment to innovation, potentially influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PCRX Stock
What is Pacira BioSciences Inc.'s (PCRX) stock forecast for 2026?
Based on our analysis of 19 Wall Street analysts, Pacira BioSciences Inc. (PCRX) has a median price target of $27.00. The highest price target is $38.00 and the lowest is $22.00.
Is PCRX stock a good investment in 2026?
According to current analyst ratings, PCRX has 4 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $23.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PCRX stock?
Wall Street analysts predict PCRX stock could reach $27.00 in the next 12 months. This represents a 16.1% increase from the current price of $23.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pacira BioSciences Inc.'s business model?
The company generates revenue by developing, manufacturing, and selling innovative non-opioid pain management products, primarily targeting acute and chronic pain. Its flagship product, EXPAREL, is a long-acting local anesthetic, while iovera offers targeted cryoneurolysis. The company focuses on enhancing patient recovery and reducing opioid dependence in various clinical settings.
What is the highest forecasted price for PCRX Pacira BioSciences Inc.?
The highest price target for PCRX is $38.00 from Douglas Tsao at HC Wainwright & Co., which represents a 63.4% increase from the current price of $23.25.
What is the lowest forecasted price for PCRX Pacira BioSciences Inc.?
The lowest price target for PCRX is $22.00 from Serge Belanger at Needham, which represents a -5.4% decrease from the current price of $23.25.
What is the overall PCRX consensus from analysts for Pacira BioSciences Inc.?
The overall analyst consensus for PCRX is bullish. Out of 19 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $27.00.
How accurate are PCRX stock price projections?
Stock price projections, including those for Pacira BioSciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 9, 2026 10:34 PM UTC